CTIS2023-507527-28-00招募中1 期
Candi5V01
immaTech Biologics AG0 个研究点目标入组 251 人开始时间: 2023年8月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 251
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapyMetastatic pancreatic ductal adenocarcinoma (mPDAC)MedDRA version: 21.0Level: LLTClassification code: 10033599Term: Pancreatic adenocarcinoma metastatic Class: 10029104CTIS2023-508998-85-00Boehringer Ingelheim International GmbH68
进行中（未招募）
1 期
A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy.EpilepsyCTIS2022-502638-17-00Trevena Inc.24
进行中（未招募）
1 期
A Study to Learn About the Taste Profiles of Different Suspensions of Study Medicine Called PF-07923568 in Healthy Adult ParticipantsRSV (respiratory syncytial virus)MedDRA version: 21.1Level: PTClassification code: 10061603Term: Respiratory syncytial virus infection Class: 100000004862CTIS2023-504924-24-00Pfizer Inc.12
招募中
1 期
Testing for the first time the effects of a new medicine in healthy peoplePsychatric disorderCTIS2023-507880-20-00Eurofins Optimed72
招募中
1 期
A study of SGN-CEACAM5C in adults with advanced solid tumorsCTIS2023-505858-18-00Seagen Inc.410